New drug NTB003 aims to reduce bulging eyes in thyroid disease
NCT ID NCT07462130
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called NTB003 in 74 people with thyroid eye disease, a condition that can cause bulging eyes and inflammation. Participants receive injections of NTB003 or a placebo every 4 weeks. The study measures whether the drug reduces eye bulging and quiets disease activity. Because it is a Phase 1b/2 trial, the main goals are safety and finding the right dose, so it is too early to know if NTB003 will become a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTB003 (a drug given by injection under the skin every 4 weeks)
What this could lead to
If successful, this could point toward a new treatment option to reduce eye bulging and inflammation in people with thyroid eye disease.
What could go wrong
This is an early-phase trial (Phase 1b/2) with only 74 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.